Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Aid, amortized, bankrupt, Bayer, borrower, BRCA, capmatinib, Citibank, coordinating, darolutamide, default, discontinue, discontinued, discontinuing, downturn, drawdown, economy, FDC, forgivable, forgiven, inter, loan, Lynparza, Mayo, Notwithstanding, Nubeqa, Olaparib, page, pandemic, Paycheck, plaintiff, PPP, preceding, premium, prepay, prepayment, Prime, promissory, Provenge, recommence, reexamination, remotely, repayment, resume, retail, Rubraca, rucaparib, St, Tabrecta, twenty, validly, Valo, virtually, waste, week
Filing tables
Filing exhibits
INTI similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-214207) of our report dated March 26, 2021 included in this Annual Report on Form 10-K of Inhibitor Therapeutics, Inc. (the “Company”), relating to the balance sheets of the Company as of December 31, 2020 and 2019, and the related statements of operations, stockholders’ equity and cash flows for the years then ended.
/s/ Cherry Bekaert LLP
Tampa, Florida
March 26, 2021